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We report on Dutch and Iranian families with affected individuals who present with moderate to severe intellectual disability and
additional phenotypes including progressive tremor, speech impairment, and behavioral problems in certain individuals. A combina-
tion of exome sequencing and homozygosity mapping revealed homozygous mutations c.484G>A (p.Gly162Arg) and c.1898C>G
(p.Pro633Arg) in SLC6A17. SLC6A17 is predominantly expressed in the brain, encodes a synaptic vesicular transporter of neutral amino
acids and glutamate, and plays an important role in the regulation of glutamatergic synapses. Prediction programs and 3D modeling
suggest that the identified mutations are deleterious to protein function. To directly test the functional consequences, we investigated
the neuronal subcellular localization of overexpressed wild-type and mutant variants in mouse primary hippocampal neuronal cells.
Wild-type protein was present in soma, axons, dendrites, and dendritic spines. p.Pro633Arg altered SLC6A17 was found in soma and
proximal dendrites but did not reach spines. p.Gly162Arg altered SLC6A17 showed a normal subcellular distribution but was associated
with an abnormal neuronalmorphologymainly characterized by the loss of dendritic spines. In summary, our genetic findings implicate
homozygous SLC6A17 mutations in autosomal-recessive intellectual disability, and their pathogenic role is strengthened by genetic
evidence and in silico and in vitro functional analyses.Introduction
Intellectual disability (ID) is a neurodevelopmental disor-
der that has a great impact on the quality of life of affected
individuals and their families.1,2 Despite its high preva-
lence of 2% in the population, so far only approximately
60% of individuals with ID receive a conclusive genetic
diagnosis.3,4 The identification of causative mutations is
complicated by the enormous genetic heterogeneity,
which is observed for all types of inheritance (dominant,
recessive, and X-linked). Particularly for non-specific types
of ID, the identification of causative mutations has been
hampered by the lack of phenotypic features that might
guide molecular analyses in both diagnostic and research
settings. To date, a handful of genes have been implicated
in non-specific forms of autosomal-recessive ID (ARID).5–7
Only recently, the combined application of SNP microar-
rays for homozygosity mapping and advancement of
next-generation sequencing technologies has accelerated
the elucidation of causative mutations in ARID, mostly
in consanguineous families and specific syndromes.7–9
In addition, exome sequencing has proven to be very
powerful in identifying the genetic defects in small
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variant, because usually multiple homozygous and com-
pound-heterozygous variants need to be considered.
Compelling evidence of causality can be obtained by the
identification of variants affecting the same gene in unre-
lated subjects who share the same phenotypic features. It
is difficult to recognize phenotypic similarity for genuine
non-specific ID; however, it often happens that features
associated with an unremarkable ID phenotype only
become apparent when clinical comparisons can be car-
ried out for individuals sharing mutations that affect the
same gene.
Here, we studied two recessive families by combining
homozygosity mapping and exome sequencing. In
SLC6A17 (MIM 610299), we identified two missense vari-
ants that segregated with the phenotype in each of the
families. Further, in silico and in vitro analyses supported
the causal effects of the identified mutations.Material and Methods
Family Ascertainment
Family W10-3099, with three affected females (II-4, II-5, and II-6;
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Figure 1. Pedigree Structures of Families W10-3099 and M328, Photographs of Affected Individuals, and Illustration of Homozygos-
ity Mapping
(A) The pedigree structure of familyW10-3099. The asterisks indicate the individuals used for homozygosity mapping and CNVanalysis.
(B) Photographs of three affected individuals of family W10-3099.
(C) The pedigree structure of family M328. The asterisks indicate the individuals used for homozygosity mapping and CNV analysis.
(D) Photographs of two affected individuals of family M328.
(E) An ideogram of chromosome 1 indicates the location of the homozygous regions at p21.1–p12. Both homozygous regions shared
12.8-Mb interval chr1: 106,037,979–118,837,958 in families W10-3099 and M328.comprising over 250 individuals (both children and adults) with
ID of unknown etiology. These individuals were selected from a
large cohort of more than 2,000 individuals living in residential
settings for people with intellectual disabilities in the eastern
part of the Netherlands.4 All of them received a clinical genetic
evaluation, including SNP array analysis, phenotype-guided
DNA analysis, and a metabolic screen. Individuals without a
conclusive diagnosis were candidates for further studies by exome
sequencing. The study was approved by the local ethics committee
of the Radboud university medical center (Nijmegen). InformedThe Ameconsent was obtained from the parents or legal representatives
of the participants.
In a simultaneous study, the consanguineous family M328
(Figure 1C), with two affected individuals (IV-1 and IV-3;
Figure 1D), was recruited among a cohort study comprising
1,000 Iranian families affected by ID with an autosomal-recessive
pattern of inheritance. The family was recruited by the Genetics
Research Center (Tehran). The affected persons were examined
for physical and mental status. Written consent was obtained
from their parents. This study was approved by the ethicsrican Journal of Human Genetics 96, 386–396, March 5, 2015 387
committee of the University of Social Welfare and Rehabilitation
Sciences (Tehran).
Homozygosity Mapping and Analysis of Copy-
Number Variation
In order to detect possible copy-number variations (CNVs) in fam-
ily W10-3099, we performed Affymetrix 250K SNP array analysis
and analyzed data with the Copy Number Analyzer for GeneChip
(v.2.0)11 (Affymetrix). Genotype calls were generated with Affyme-
trix Genotyping Console (v.2.1) software. The shared runs of
homozygosity (ROHs) were determined with PLINK (v.1.06).12 In
each window of 50 SNPs, up to five SNPs with a missing call and
a maximum of two heterozygous called SNPs were allowed. We
used a cutoff of 1 Mb to identify shared ROHs.13 In order to screen
additional individuals, we used the same criteria described above
to determine the ROHs in an additional cohort of >5,000 idio-
pathic ID individuals who were systematically ascertained at our
institute. We selected individuals with ROHsR 5 Mb in size.
To detect ROHs in common between the affected individuals in
family M328, we mixed genomic DNA from individuals IV-1 and
IV-3 in an equimolar concentration. The DNAmixture was hybrid-
ized to the Genome-wide Human SNP Array 6.0 (Affymetrix) with
a resolution of one million SNPs. Data were analyzed with Partek
Genomics Suite software.
Exome Sequencing
Exome enrichment was performed with the Agilent v.2 XT Multi-
plex (BC7) Enrichment Kit (Agilent) with DNA from individual II-
6 of family W10-3099. Emulsion PCR and bead preparation were
performedwith theEZbead systemaccording to themanufacturer’s
(Life Technologies) instructions. We used the SOLiD v.4 platform
(Life Technologies). A total of 8.4 Gb of sequence was obtained
and mapped to the human reference genome (UCSC Genome
Browser hg19) with LifeScope v.2.1 software (Life Technologies).
DNA from individual IV-1 of family M328 was analyzed by
exome sequencing as described before.14 In brief, a whole-exome
sequencing library was prepared with the SureSelect Human All
Exon 50 Mb Kit (Agilent Technologies) in accordance with the
manufacturer’s protocol. The captured library was sequenced
with a Hi-Seq 2000 sequencing system (Illumina) in accordance
with the manufacturer’s protocol.
Sanger Sequencing
Primers for the amplification of exons and exon-intron boundaries
were designed with the Primer3 program15 for SLC6A17 as well as
for other identified rare variants in their respective genes. PCR
products were purified with a NucleoFast 96 PCR plate (Clontech
Lab) according to the manufacturer’s protocol. We used the ABI
PRISM BigDye Terminator Cycle Sequencing v.3.1 Ready Reaction
Kit and the ABI PRISM 3730 DNA Analyzer (Applera Corporation)
to perform sequence analysis.
Molecular Modeling
The 3D structure of SLC6A17 has not yet been solved experimen-
tally. Therefore, we used the structure of the leucine transporter
(LeuT) as a template to build a homology model of SLC6A17.
PDB identifier 3GWU16 contains a sequence of Aquifex aeolicus
VF5 LeuT, which has a sequence identity of 24.4% with that of
SLC6A17 over a stretch of 447 residues. The (partial) model was
built with the automatic modeling script in the YASARA17 and
WHAT IF18 Twinset with standard parameters.19388 The American Journal of Human Genetics 96, 386–396, March 5Slc6a17 Neurodevelopmental Expression Analysis in
Mouse Brain Tissues
We used mouse neurodevelopmental TissueScanTMqPCR Arrays
(OriGene Technologies) to screen for Slc6a17 expression in a total
of 48 different brain regions in five neurodevelopmental stages
(embryonic days 13, 15, and 18, postnatal day 7, and adult week
5) by using SsoAdvanced Universal SYBR Green Supermix (Bio-
Rad) gene-expression assays according to the manufacturer’s
instructions. These arrays contained pre-standardized amounts
of cDNA according to the manufacturer’s specifications. The
cDNA was amplified by PCR with Slc6a17-specific primers located
in exons 9 and 10 (Table S2). Quantification was carried out with a
method derived from the 2DDCp method.20 A normalized ratio
was obtained for each target gene with LC480 software (Roche),
qPCR efficiencies were 100%, and Gapdh (glyceraldehyde 3-phos-
phate dehydrogenase) was used as a reference gene.
Generation of Wild-Type and Mutant Mouse Slc6a17
Constructs for Overexpression Studies
For transient expression, full-length open reading frames of mouse
wild-type (WT) and mutant Slc6a17 constructs were amplified
from the IMAGE clone 950654248, which contains the mouse
Slc6a17 cDNA (GenBank accession number BC171962; Source
Bioscience), with primer set Slc6a17-GFPinfus-Fd and Slc6a17-
GFPinfus-Rv (Table S2). PCR products were inserted into the
pAcGFP1-N In-Fusion Ready Vector (Clontech) with the In-Fusion
HD Cloning Kit (Clontech). The clones with mutations c.484G>A
(p.Gly162Arg) and c.1898C>G (p.Pro633Arg) were first generated
in two PCR fragments including an overlapping region containing
the mutation (Table S2). The PCR fragments were then inserted
into the pAcGFP1-N In-Fusion Ready Vector with the In-Fusion
HD Cloning Kit. Correctness of all sequences was determined by
Sanger sequencing. The Slc6a17-WT-GFP, Slc6a17-p.Gly162Arg-
GFP, and Slc6a17-p.Pro633Arg-GFP constructs were then used for
transfection studies in primary neuronal cultures.
Mouse Primary Neuronal Cultures
All mouse experiments were performed according to protocols
approved by the University Francois-Rabelais of Tours and
INSERM. Hippocampi or cortices were dissected from embryonic
day 17.5 C57BL/6J mouse embryos (Janvier), manually dis-
persed in cold PBS (Fisher Scientific), and triturated with papain
(10 U/ml; Worthington) for 22 min at 37C. Cells were resus-
pended in Dulbecco’s modified Eagle’s medium/F12 (Fisher Scien-
tific) with 10% fetal bovine serum (Eurobio) and centrifuged at
2503 g for 3 min, and the final pellet was resuspended in primary
neuron growth medium (PNGM; Lonza). Dissociated cells were
then plated onto glass coverslips coated in poly-D-lysine (Sigma)
and laminin at a density of 400 cells per mm2. The cultures were
kept in PNGM, and half of the mediumwas changed twice a week.
Transfection
Hippocampal neurons were transfected on days 10–12 in vitro
with the appropriate plasmids (WT and mutated forms of
Slc6a17) with the Magnetofectamine Transfection Kit (OZ Biosci-
ences). In brief, 1 mg of DNA was combined with 2 ml of Lipofect-
amine 2000. The DNA and Lipofectamine 2000 mixture was
immediately added to 1 ml of CombiMag and incubated for
20 min at room temperature. Complexes were added dropwise
onto cells growing in serum-containing culture medium. Next,
cells were incubated for 15 min on the magnetic plate at room, 2015
temperature. After incubation, medium was changed, and the
magnetic plate was removed. Microscopy analyses were carried
out 24–48 hr after transfection.Immunocytochemistry
Transfected primary neurons were fixed with 4% paraformalde-
hyde at room temperature for 20 min and permeabilized with
PBS (Fisher Scientific), 3% BSA (Interchim), and 0.2% Triton
X-100 (Sigma) for 1 hr at room temperature. The following incuba-
tions were performed with blocking solution (PBS, 3% BSA, and
0.2% Triton X-100) at room temperature. Cells were first incubated
for 1 hr at room temperature with primary antibodies diluted in
blocking solution: monoclonal mouse anti-PSD95 (1/100; Fisher
Scientific), goat anti-VGLUT1 (1/50; Clinisciences), and mouse
anti-synaptophysin (1/50; Abcam). After three washes in PBS
for 5 min each, the secondary antibody (FluoProbes FP-594
donkey anti-mouse and anti-goat antibodies, 1/300; Interchim)
was diluted in blocking solution and incubated with the neurons
for 45 min in dark conditions. No staining was detected when
primary antibodies were not added in parallel preparations (data
not shown). The cells were mounted with the DAPI ProLong
gold antifade solution (Fisher Scientific).Image Analysis
The neuronal cellular-imaging study was performed at the micro-
scopy research platform of the University of Tours. Sequential
acquisitionsweremade, and high-resolution z stack images of neu-
rons were taken with the 633 plan apochromat objective of a
confocal FluoView 500microscope (Olympus) with optical section
separation (z interval) of 0.5–0.7 mm. Maximal projections were
made for image production.Results
Clinical Description
Family W10-3099 was ascertained as an ARID-affected
family. This family has three affected females (II-4, II-5,
and II-6) and three healthy siblings (Figures 1A and 1B).
Pregnancy and birth of the three affected individuals
were uncomplicated. In the neonatal period, they cried
excessively. Psychomotor development was delayed from
birth. Specific timeframes for these childhood milestones
were not available because individuals II-4, II-5, and II-6
were seen at 64, 62, and 60 years of age, respectively, and
no previous documentation was present. Their develop-
mental age was between 1 and 4 years. They could speak
up to three-word sentences. Their behavior was character-
ized by mood instability, aggression, and self-mutilation.
Between 40 and 50 years of age, they developed a progres-
sive essential hand tremor, which manifested as an inten-
tional tremor and slight tremor at rest. This was not
present in their healthy siblings. One of the affected sisters
(II-5) had a renal anomaly, including a double renal pelvis
with double ureter. One of the affected individuals (II-6)
had an incidental epileptic insult at 40 years of age. How-
ever, no seizures were further reported. Electroencephalog-
raphy (EEG) was performed in all three affected family
members, but no epileptic features were found. In one ofThe Amethe sisters (II-5), a cerebral computed-tomography scan
was taken when she was 55 years old. Results were normal.
In the other two sisters, cerebral imaging was not per-
formed. Individual II-6 developed melanoma at 48 years
of age and breast cancer at 50 years of age. Individual II-5
was diagnosed with endometrium carcinoma at 59 years
of age. Tumor characteristics and ages of presentation
were not suggestive of hereditary cancer. The three sisters
had a normal height (5th–20th percentile) and normal
head circumference (20th–50th percentile). Facial dysmor-
phisms included large ears, a prominent chin, narrow
palpebral fissures, a long philtrum, and a slightly high
and narrow palate (Figure 1B). In addition, they had small
hands (<3rd percentile; Table 1). They had a waddling
walking pattern. Metabolic screening in the serum and
urine of individual II-6 and in the serum of individual II-
4 included quantification of amino acids, creatine biosyn-
thesis, carnitines, very-long-chain fatty acids, transferrin
subfractions, mucopolysaccharides, purines and pyrimi-
dines, and organic acids. All the values were found in the
normal range. The analysis of FMR1 (MIM 309550) in indi-
vidual II-4 did not reveal evidence of expansion of the
CGG repeat.
In the Iranian family (M328), two affected individuals
(IV-1 and IV-3; Figures 1C and 1D) and two healthy siblings
(IV-2 and IV-4) were born to first-cousin consanguineous
parents (Figure 1C). Affected individuals IV-1 and IV-3
(now aged 22 and 20 years, respectively) were initially
referred for intellectual disability. Pre-, peri-, and postnatal
periods were uneventful. They had severe mental impair-
ment (IQs of 29 and 30 for IV-1 and IV-3, respectively)
and no speech development. Progressive essential tremors
of the hands developed in both IV-1 and IV-3 at the age of
13 and 16 years, respectively. Progressive tremors were
not seen in the healthy family members. Brain imaging
and EEG were not performed in the affected individuals.
The behavioral problems were mainly characterized by
aggressiveness and poor impulse control in both affected
persons. They were not able to walk and were unable to
take care of themselves. They had normal head circumfer-
ence (50th percentile) and normal height (25th percentile).
They had normal length of hands (50th percentile) (Table
1). Facial features included large ears, a prominent chin,
thick eyebrows, and slightly narrow palpebral fissures
(Figure 1D). Karyotype analysis by G-banding and tandem
mass spectrometry screening for metabolic disorders as
well as FMR1 screening were performed for individual IV-
3. None of these tests revealed any chromosomal aberra-
tions or mutations that could explain the phenotype.
Genetic Analysis
In family W10-3099, CNV analysis did not reveal any
pathogenic aberrations. We performed homozygosity
mapping on individuals II-4, II-5, and II-6. A single shared
ROH of 12.8 Mb in size was identified in chromosomal
region 1p21.1–p12 (chr1: 106,037,979–118,837,958), en-
compassing about 155 genes (Figure 1E). To identify therican Journal of Human Genetics 96, 386–396, March 5, 2015 389
Table 1. Clinical Features of Affected Members of Families W10-3099 and M328
Family W10-3099 Family M328
II-4 II-5 II-6 IV-1 IV-3
Age 64 years 62 years 60 years 22 years 20 years
Consanguinity no no no yes yes
Height
(percentile)
161 cm (<10%) 164 cm (15%) 165 cm (20%) 150 cm (25%) 152 cm (25%)
Head circumference
(percentile)
56 cm (>50%) 55.4 cm (25%) 54 cm (20%) 54 cm (50%) 56 cm (50%)
Intellectual
disability
moderate to severe moderate to severe severe severe (IQ 29) severe (IQ 30)
Tremor progressive progressive progressive progressive progressive
Behavior inappropriate laughter,
compulsive, mood
instability
mood instability aggressive, compulsive,
mood instability
aggressive, poor
impulse control
aggressive, poor
impulse control
Hand length
(percentile)
(3%) small (3%) normal (50%) normal (50%)
Other – congenital renal anomaly
(double renal pelvis with double
ureter), endometrium carcinoma
at 59 years of age
hypothyroidism, incidental
epileptic insult, melanoma
at 48 years of age, breast
cancer at 50 years of age
no nogenetic defect in this family, we performed exome seq-
uencing. From our exome data, we obtained a median
coverage of 1033, and 89% of targets were covered at least
103. A total of 14,986 variants were identified in coding
regions and canonical splice sites. Prioritization was done
as described before.21,22 Variants that are known in
dbSNP134 and in our in-house database, which consists
of 672 samples from healthy and affected individuals
with other rare disorders, were excluded. After this filter
was applied, the number of variants was reduced to 299.
Further prioritization was performed on the basis of an
autosomal-recessive model of inheritance, resulting in 21
candidate genes: 18 with potential homozygous variants
(>80% variant reads) and three with compound-heterozy-
gous variants (20%–80% variant reads). We analyzed all
of these variants by inspecting the raw read alignment
files (BAM files) in order to determine the presence and
the minimal percentage (20%) of the variant reads,
which reduced the number of candidate genes to ten
with homozygous variants and two with compound-het-
erozygous variants. We excluded two genes, TAS1R3
(MIM 605865) and MUC16 (MIM 606154), because
these are commonly found in the exome data to carry
either homozygous or compound-heterozygous variants.
Another gene, CWH43, was excluded because frequent
(1.2%) truncating variants are encountered in this
gene in the NHLBI Exome Sequencing Project Exome
Variant Server (EVS). After this, eight homozygous
variants and one compound-heterozygous variant were
left (Table S1). All the identified variants were tested
by Sanger sequencing. None but a single homozygous
variant, chr1:110716634G>A (c.484G>A [p.Gly162Arg]),
in SLC6A17 (RefSeq accession number NM_001010898.2)390 The American Journal of Human Genetics 96, 386–396, March 5segregated with the phenotype (Figure 2A). This variant
is located in SLC6A17 exon 4, whichmaps to the identified
12.8 Mb homozygous region in 1p21.1–p12 (Figure 1E).
It has a phyloP score of 6.3 (Table S1) and a Grantham
score of 125. Gly162 was found to be highly conserved
down to zebrafish (Figure 2D). The uncharged Gly162,
which is replaced by a positively charged arginine residue,
is located in the third transmembrane domain of the
protein (Figure 2C). We used three prediction programs—
PolyPhen2,23 SIFT,24 and SNPs&GO25—to predict the
pathogenic nature of the identified missense variant. All
three prediction programs classified c.484G>A as ‘‘possibly
damaging.’’ A Combined Annotation Dependent Deple-
tion (CADD)26 score of 34 was observed for this variant.
The missense mutation was absent from dbSNP138, 1000
Genomes, and the NHLBI EVS.
In family M328, CNV analysis did not reveal any patho-
genic structural changes. Homozygosity mapping revealed
eight shared ROHs (Table S3). We performed whole-exome
sequencing in one affected individual (IV-1). Sequencing
was carried out in a 101-nt single-end sequencing for-
mat and showed 95% coverage and an average depth of
52 reads. To detect single-nucleotide variants, we aligned
high-quality reads to the human reference genome
(UCSC Genome Browser hg19) with Short Oligonucleotide
Analysis Package (SOAP) 2.20. Variant lists were filtered
against dbSNP137, whole genomes from 185 healthy indi-
viduals studied by the 1000 Genomes Project, exomes
from 200 Danish individuals, andmore than 6,500 exomes
present in the NHLBI EVS. In addition, variants were
compared to an in-house database containing more than
200 exomes. Variants were ranked as potential candidates
as previously described27 with an improved version of, 2015
Figure 2. Segregation Analysis and Schematic Representation of the Protein, Including the Location and Conservation of the Iden-
tified Amino Acid Changes
(A) Chromatograms revealing the complete segregation of homozygous missense mutation chr1:110716634G>A (c.484G>A
[p.Gly162Arg]) with the phenotype in family W10-3099.
(B) Chromatograms show complete segregation of homozygous missense mutation chr1:110740780C>G (c.1898C>G [p.Pro633Arg])
with the phenotype in family M328.
(C) A schematic representation of SLC6A17 indicates the location of both alterations on the 3rd and 12th transmembrane domains.
(D) Partial amino acid sequence alignment of human SLC6A17 and its homologs in the animal kingdom. The positions of the amino acid
substitutions—p.Gly162Arg in familyW10-3099 and p.Pro633Arg in familyM328—are indicated by red rectangles. Both altered residues
are conserved down to zebrafish.the Medical Re-sequencing Analysis Pipeline (MERAP).28
In addition, we used OMIM and the Human Gene Muta-
tion Database (HGMD) as filters to identify all previously
described pathogenic changes.
After filtering thevariants byusing an improvedversionof
theMERAP algorithm and their annotationwith RefSeq, we
ranked two homozygous missense variants—SLC6A17
chr1:110740780C>G (c.1898C>G [p.Pro633Arg]) and
FAM213B chr1:2519225T>G (c.404T>G [p.Phe135Cys])—
as potentially pathogenic. Both are located in identified
homozygous regions. Upon co-segregation testing, onlyThe Amethe SLC6A17 mutation segregated with the disease in the
family (Figure 2B). SLC6A17 is located in the largest homo-
zygous region (Figure 1E; Table S3), and the identifiedmuta-
tion is present in exon 12 of the gene. SLC6A17 c.1898C>G
was not reported in dbSNP138, 1000 Genomes, or the
NHLBI EVS. Moreover, the variant was absent in our in-
house database containingmore than 200 exomes. Themu-
tation affects a highly conserved amino acid (Figure 2D). In
line with this, the phyloP score was found to be 5.3, and
theGrantham score was 103. The uncharged Pro633, which
is replaced by a positively charged arginine residue, isrican Journal of Human Genetics 96, 386–396, March 5, 2015 391
located in the 12th transmembrane domain of the protein
(Figure 2C). In silico analyses with several pathogenicity
prediction programs, including SIFT, PolyPhen-2, and
SNPs&Go, predicted the amino acid substitution to be
damaging to the protein function. A CADD score of 23.8
was obtained for this variant.
In order to find other possible homozygous muta-
tions, we selected 18 additional unrelated ID subjects
(both consanguineous and non-consanguineous) with
shared homozygosity of a >5 Mb region encompassing
SLC6A17. These individuals were selected from a large
cohort of individuals (>5,000) who lacked a molecular
diagnosis and were seen at the Department of Human Ge-
netics of Radboud university medical center (Nijmegen).
We performed Sanger sequencing in these individuals to
sequence all the exons and intron-exon boundaries of
SLC6A17. The sequencing analysis did not reveal any
potentially pathogenic variants (data not shown).
Molecular Modeling
To collect further evidence of the causality of the identified
variants, we performed prediction analysis with the 3D
protein structure. Gly162 is located in an alpha helix
that also contains residues that form the substrate binding
site (Figures S1A and S1B). Gly162 is not in contact with
the substrate but instead is located on the opposite side
of the helix. The substitution converts this residue into
an arginine, a large hydrophilic amino acid whose side
chain most likely does not fit at this position and causes
a clash with Leu231, located on helix 4. This model sug-
gests that p.Gly162Arg affects protein structure and poten-
tially interferes with the function of the protein. Pro633 is
located in one of the helices on the surface of the protein
and is far from the ligand binding site (Figures S1A
and S1C). This hydrophobic proline is in contact with
membrane lipids and could be important for anchoring
SLC6A17 in the membrane. Substitution of arginine at
this position could interfere with protein function by dis-
turbing the membrane anchoring given that it is a hydro-
philic, charged residue.
Slc6a17 Is Expressed in the Central and Peripheral
Nervous Systems
To get more insight into the expression pattern of
SLC6A17, we performed a quantitative cDNA analysis
of the orthologous mouse Slc6a17 in a panel represen-
ting 40 distinct mouse tissues. Slc6a17 expression levels
increased during embryonic brain development, and the
highest levels were observed postnatally. This suggests
that an important role for Slc6a17 during brain develop-
ment starts in the neuritogenesis and synaptogenesis
stages. The strongest expression levels in embryonic,
postnatal, and adult stages were found in both cortical
and hippocampal tissues (Figure S2). Our data are also
in accordance with a recent study that described the
Slc6a17 mRNA expression pattern in the mouse adult
brain.29392 The American Journal of Human Genetics 96, 386–396, March 5Subcellular Localization of WTandMutant Slc6a17 in
Mouse Embryonic Hippocampal Primary Neurons
To assess the functional impact of both variations in
SLC6A17, we transfected mature mouse embryonic pri-
mary hippocampal neuronal cultures with plasmids, lead-
ing to the overexpression of WT or variant forms of
SLC6A17-GFP fusion proteins.
Confocal-microscopy analyses indicated a wide sub-
cellular localization of SLC6A17-WT-GFP throughout the
cells; compared to GFP-overexpressing neurons, these cells
showed no alteration in neuronal morphology (data not
shown). SLC6A17-WT-GFP was partly present at dendritic
spines (arrows, Figure 3A) and colocalized with PSD95
(an excitatory post-synaptic marker) and was also present
at pre-synaptic sites, as indicated by the pre-synaptic
markers VGLUT and synaptophysin (Figure 3B). Our data
suggest that SLC6A17-WT-GFP is localized at synaptic junc-
tions—at both pre- and post-synaptic sites—particularly in
excitatory glutamatergic terminals, in agreement with a
recent study by Ha¨gglund et al.,29 who studied the endoge-
nous localization pattern of SLC6A17 in the rat brain.
By contrast, the analysis of the subcellular localization of
p.Gly162Arg and p.Pro633Arg SLC6A17 variants revealed
different findings. Whereas SLC6A17-p.Gly162Arg-GFP
displayed a wide distribution within the cell, the mor-
phology of transfected mature neurons was altered and
characterized by a systematic loss of dendritic spines
(Figure 4A). In addition, SLC6A17-p.Pro633Arg-GFP was
observed in soma and proximal dendrites, but not in spinal
structures, contrary to theWT form (Figure 4B). The overall
neuronal morphology was not affected in a comparison of
SLC6A17-WT-GFP and GFP-overexpressing neurons.Discussion
In this study, we have identified SLC6A17 mutations in
individuals with an ARID phenotype. Two independent
mutations were identified in two families with different
ethnic backgrounds. In silico analysis based on Poly-
Phen-2, SIFT, and SNPs&GO predicted ‘‘damaging’’ effects
of the identifiedmissense variants on the protein function.
Moreover, 3D modeling revealed that identified amino
acid substitutions are predicted to result in a conforma-
tional change influencing normal SLC6A17 function. To
further test this notion, we performed functional analyses
by using primary hippocampal neuronal cells from mouse
embryos. Our in vitro data obtained from transfected
primary neurons indicate that the p.Gly162Arg and
p.Pro633Arg amino acid substitutions in SLC6A17 affect
either its dendritic localization or the neuronal mor-
phology and suggest a specific pathophysiological mecha-
nism possibly linked to the protein domains including
the Gly162 or the Pro633 amino acids. It should, however,
be noted that our in vitro data were obtained from overex-
pression experiments of eitherWTor altered SLC6A17-GFP
and thus might not perfectly reflect the in vivo conditions., 2015
Figure 3. Subcellular Neuronal Localiza-
tion of SLC6A17-GFP
(A) Mature hippocampal neurons (11–
19 days in vitro) were co-transfected with
Slc6a17-GFP and DsRed. A zoomed part
of the cell (white rectangle) provides
higher resolution regarding the localiza-
tion in dendritic spines (arrows) (n ¼ 5
transfections, 38 cells analyzed). Scale
bars represent 50 mm.
(B) Mature hippocampal neurons (11–
19 days in vitro) were transfected with
Slc6a17-GFP and then analyzed by immu-
nocytochemistry against PSD95, VGLUT,
or synaptophysin. (n ¼ 3 transfections,
12 cells analyzed). Scale bars represent
10 mm.
Asterisks indicate colocalization of SLC
6A17-GFP and a synaptic marker; plus
signs indicate juxtaposition of SLC6A17-
GFP and a synaptic marker.On the basis of the clinical features from the two fam-
ilies, the phenotypic spectrum that could be caused by
SL6A17 mutations comprises moderate to severe ID with
hardly any speech development, progressive tremors,
and behavioral problems. Motor development might also
be severely impaired, possibly inhibiting independentThe American Journal of Humanwalking. There is no distinct facial
phenotype. Remarkably, all affected
individuals from family W10-3099
had small hands, whereas this was
not present in the affected members
of the Iranian family (M328).
SLC6 family genes encode struc-
turally related Naþ-dependent trans-
porter proteins. They are responsible
for the re-uptake of many neuro-
transmitters.30 SLC6A17 encodes a
vesicular transporter protein, also
known as XT1 or NTT4.31 This pro-
tein is predominantly localized in
the nervous system, specifically in
glutamatergic and some GABAergic
neurons.32,33 SLC6A17 functions as
a selective transporter of four amino
acids (proline, glycine, leucine, and
alanine), as well as glutamate.34,35
Recently, it has been shown that it
is involved in regulating glutamater-
gic synapses.29 Proline has a role in
producing electrophysiological ac-
tions in the brain.36,37 Moreover, it
has been demonstrated that physio-
logically increased levels of L-proline
are localized in many neurons,38
but understanding the specific role
of proline in synaptic transmis-
sion will require further studies.34Glycine acts both as an inhibitory neurotransmitter and
as an activator of ionotropic glutamate N-methyl-D-
aspartate (NMDA) receptors. NMDA receptors are distrib-
uted all over the brain and wire different functions such
as synaptic plasticity and development of learning and
memory. NMDA receptor activation requires both glycineGenetics 96, 386–396, March 5, 2015 393
Figure 4. Functional Analysis of SLC6A17 Alterations in Mature Primary Hippocampal Neurons
(A) Primary neuronal cultures were co-transfected at 14 days in vitro with Slc6a17-p.Gly162Arg-GFP and pDsRedmonomer (for whole-
cell labeling) and visualized 48 hr later on confocal microscopy under living condition (n¼ 7 transfections, 46 cells analyzed). Scale bars
represent 50 mm (neuron) and 10 mm (zoomed image).
(B) Confocal images of mature hippocampal neurons (16 days in vitro) transfected with Slc6a17-p.Pro633Arg-GFP and pDsRedmonomer
(n ¼ 3 transfections, 6 cells analyzed). Scale bars represent 50 mm (neuron) and 10 mm (zoomed image).and glutamate. It is known that fluctuation in the extra-
cellular concentration of glycine can alter the functions
of NMDA receptors. Several independent studies have
shown that such NMDA alterations are involved in neu-
rodevelopmental and neuropsychiatric disorders such as
cognitive impairment and schizophrenia.39,40 The role
of leucine and alanine in synaptic transmission is not
known.34 It would have been very instructive to obtain
the amino acid profile in cerebrospinal fluid of the
affected individuals, but none of the individuals or guard-
ians wished to participate in such invasive investigations.
Another SLC6 Naþ-dependent transporter protein, the
creatine transporter SLC6A8, has been implicated in
cerebral creatine deficiency syndrome 1 (MIM 300352),
which includes ID as a main feature.41 It is proposed
that dysfunction of the inhibitory neurotransmitters
GABA and glycine plays a role in the development of
essential tremor.42–44 The impairment of the GABAergic
system is also involved in fragile X syndrome (MIM
300624) and fragile X tremor/ataxia syndrome (FXTAS
[MIM 300623]).45
In conclusion, we have identified SLC6A17 mutations
that are associated with ARID. Our data are supported by
genetic recurrence and in silico and in vitro analyses.
Further testing of SLC6A17 in individuals with similar phe-
notypes or unbiased ARID screening might elucidate the394 The American Journal of Human Genetics 96, 386–396, March 5involvement of this gene in cognitive function as well as
establish the phenotypic spectrum.Supplemental Data
Supplemental Data include two figures and three tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
2015.01.010.Acknowledgments
We are thankful to all the participating family members in this
study. Special thanks go to Annette Schenck, Bonnie Nijhof, and
Misa Fenckova for discussions on different experiments. This
work was supported by the European Union’s Seventh Framework
Programme under grant agreement number 241995 (project
GENCODYS to H.v.B., F.L., L.M., H.H.R., and H.H.), the Max-
Planck Society, the Dutch Brain Foundation under grant number
2010(1)-30 to A.P.M.d.B., the consortium ‘‘Stronger on your own
feet’’ to T.K. and M.H.W., and the Netherlands Organisation for
Health Research and Development (ZonMW) under grant number
907-00-365 to T.K. Z.I. was supported by the Higher Education
Commission of Islamabad (Pakistan).
Received: November 12, 2014
Accepted: January 6, 2015
Published: February 19, 2015, 2015
Web Resources
The URLs for data presented herein are as follows:
GenBank, http://www.ncbi.nlm.nih.gov/genbank
HGMD, http://www.biobase-international.com/product/hgmd
MERAP, https://sourceforge.net/projects/merap
NHLBI Exome Sequencing Project (ESP) Exome Variant Server,
http://evs.gs.washington.edu/EVS/
OMIM, http://www.omim.org
PDB, http://www.rcsb.org/pdb/home/home.do
PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/
Primer3, http://primer3.ut.ee/
PubMed, http://www.ncbi.nlm.nih.gov/pubmed
RefSeq, http://www.ncbi.nlm.nih.gov/refseq/
SIFT, http://sift.jcvi.org/
SNPs&GO, http://snps-and-go.biocomp.unibo.it/snps-and-go/
SOAP, http://soap.genomics.org.cn/
UCSC Genome Browser, http://genome.ucsc.edu/cgi-bin/
hgGatewayReferences
1. Leonard, H., andWen, X. (2002). The epidemiology of mental
retardation: challenges and opportunities in the new millen-
nium. Ment. Retard. Dev. Disabil. Res. Rev. 8, 117–134.
2. Roeleveld, N., Zielhuis, G.A., and Gabree¨ls, F. (1997). The prev-
alence of mental retardation: a critical review of recent litera-
ture. Dev. Med. Child Neurol. 39, 125–132.
3. Gilissen, C., Hehir-Kwa, J.Y., Thung, D.T., van de Vorst, M.,
van Bon, B.W., Willemsen, M.H., Kwint, M., Janssen, I.M.,
Hoischen, A., Schenck, A., et al. (2014). Genome sequencing
identifies major causes of severe intellectual disability. Nature
511, 344–347.
4. Willemsen, M.H., and Kleefstra, T. (2014). Making headway
with genetic diagnostics of intellectual disabilities. Clin.
Genet. 85, 101–110.
5. Ropers, H.H. (2010). Genetics of early onset cognitive impair-
ment. Annu. Rev. Genomics Hum. Genet. 11, 161–187.
6. van Bokhoven, H. (2011). Genetic and epigenetic networks in
intellectual disabilities. Annu. Rev. Genet. 45, 81–104.
7. Iqbal, Z., and van Bokhoven, H. (2014). Identifying genes
responsible for intellectual disability in consanguineous fam-
ilies. Hum. Hered. 77, 150–160.
8. Ellison, J.W., Rosenfeld, J.A., and Shaffer, L.G. (2013). Genetic
basis of intellectual disability. Annu. Rev. Med. 64, 441–450.
9. Musante, L., and Ropers, H.H. (2014). Genetics of recessive
cognitive disorders. Trends Genet. 30, 32–39.
10. Schuurs-Hoeijmakers, J.H., Vulto-van Silfhout, A.T., Vissers,
L.E., van de Vondervoort, I.I., van Bon, B.W., de Ligt, J., Gilis-
sen, C., Hehir-Kwa, J.Y., Neveling, K., del Rosario, M., et al.
(2013). Identification of pathogenic gene variants in small
families with intellectually disabled siblings by exome
sequencing. J. Med. Genet. 50, 802–811.
11. Nannya, Y., Sanada, M., Nakazaki, K., Hosoya, N., Wang, L.,
Hangaishi, A., Kurokawa, M., Chiba, S., Bailey, D.K., Kennedy,
G.C., and Ogawa, S. (2005). A robust algorithm for copy
number detection using high-density oligonucleotide single
nucleotide polymorphism genotyping arrays. Cancer Res.
65, 6071–6079.
12. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-The Amegenome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
13. Schuurs-Hoeijmakers, J.H., Hehir-Kwa, J.Y., Pfundt, R., van
Bon, B.W., de Leeuw, N., Kleefstra, T., Willemsen, M.A., van
Kessel, A.G., Brunner, H.G., Veltman, J.A., et al. (2011). Homo-
zygosity mapping in outbred families with mental retarda-
tion. Eur. J. Hum. Genet. 19, 597–601.
14. Bainbridge, M.N., Hu, H., Muzny, D.M., Musante, L., Lupski,
J.R., Graham, B.H., Chen,W., Gripp, K.W., Jenny, K., Wienker,
T.F., et al. (2013). De novo truncating mutations in ASXL3 are
associated with a novel clinical phenotype with similarities to
Bohring-Opitz syndrome. Genome Med 5, 11.
15. Rozen, S., and Skaletsky, H. (2000). Primer3 on the WWW for
general users and for biologist programmers. Methods Mol.
Biol. 132, 365–386.
16. Zhou, Z., Zhen, J., Karpowich, N.K., Law, C.J., Reith, M.E., and
Wang, D.N. (2009). Antidepressant specificity of serotonin
transporter suggested by three LeuT-SSRI structures. Nat.
Struct. Mol. Biol. 16, 652–657.
17. Krieger, E., Koraimann, G., and Vriend, G. (2002). Increasing
the precision of comparative models with YASARA NOVA—a
self-parameterizing force field. Proteins 47, 393–402.
18. Vriend, G. (1990). WHAT IF: a molecular modeling and drug
design program. J. Mol. Graph. 8, 52–56, 29.
19. Krieger, E., Joo, K., Lee, J., Lee, J., Raman, S., Thompson, J.,
Tyka, M., Baker, D., and Karplus, K. (2009). Improving phys-
ical realism, stereochemistry, and side-chain accuracy in ho-
mology modeling: Four approaches that performed well in
CASP8. Proteins 77 (9), 114–122.
20. Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative
gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods 25, 402–408.
21. Hoischen, A., Gilissen, C., Arts, P., Wieskamp, N., van der
Vliet, W., Vermeer, S., Steehouwer, M., de Vries, P., Meijer,
R., Seiqueros, J., et al. (2010). Massively parallel sequencing
of ataxia genes after array-based enrichment. Hum. Mutat.
31, 494–499.
22. Vissers, L.E., de Ligt, J., Gilissen, C., Janssen, I., Steehouwer,
M., de Vries, P., van Lier, B., Arts, P.,Wieskamp, N., del Rosario,
M., et al. (2010). A de novo paradigm for mental retardation.
Nat. Genet. 42, 1109–1112.
23. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gera-
simova, A., Bork, P., Kondrashov, A.S., and Sunyaev, S.R.
(2010). A method and server for predicting damaging
missense mutations. Nat. Methods 7, 248–249.
24. Ng, P.C., and Henikoff, S. (2003). SIFT: Predicting amino acid
changes that affect protein function. Nucleic Acids Res. 31,
3812–3814.
25. Calabrese, R., Capriotti, E., Fariselli, P., Martelli, P.L., and Casa-
dio, R. (2009). Functional annotations improve the predictive
score of human disease-related mutations in proteins. Hum.
Mutat. 30, 1237–1244.
26. Kircher, M., Witten, D.M., Jain, P., O’Roak, B.J., Cooper, G.M.,
and Shendure, J. (2014). A general framework for estimating
the relative pathogenicity of human genetic variants. Nat.
Genet. 46, 310–315.
27. Najmabadi, H., Hu, H., Garshasbi, M., Zemojtel, T., Abedini,
S.S., Chen, W., Hosseini, M., Behjati, F., Haas, S., Jamali, P.,
et al. (2011). Deep sequencing reveals 50 novel genes for reces-
sive cognitive disorders. Nature 478, 57–63.
28. Hu,H.,Wienker, T.F.,Musante, L., Kalscheuer,V.M.,Kahrizi, K.,
Najmabadi, H., and Ropers, H.H. (2014). Integrated sequencerican Journal of Human Genetics 96, 386–396, March 5, 2015 395
analysis pipeline provides one-stop solution for identifying
disease-causing mutations. Hum. Mutat. 35, 1427–1435.
29. Ha¨gglund, M.G., Hellsten, S.V., Bagchi, S., Ljungdahl, A., Nils-
son, V.C., Winnergren, S., Stephansson, O., Rumaks, J., Svir-
skis, S., Klusa, V., et al. (2013). Characterization of the
transporterB0AT3 (Slc6a17) in the rodent central nervous
system. BMC Neurosci. 14, 54.
30. Kristensen, A.S., Andersen, J., Jørgensen, T.N., Sørensen, L.,
Eriksen, J., Loland, C.J., Strømgaard, K., and Gether, U.
(2011). SLC6 neurotransmitter transporters: structure, func-
tion, and regulation. Pharmacol. Rev. 63, 585–640.
31. Chen, N.H., Reith, M.E., and Quick, M.W. (2004). Synaptic
uptake and beyond: the sodium- and chloride-dependent
neurotransmitter transporter family SLC6. Pflugers Arch.
447, 519–531.
32. Bro¨er, S. (2006). The SLC6 orphans are forming a family of
amino acid transporters. Neurochem. Int. 48, 559–567.
33. Liu, Q.R., Mandiyan, S., Lo´pez-Corcuera, B., Nelson, H., and
Nelson, N. (1993). A rat brain cDNA encoding the neurotrans-
mitter transporter with an unusual structure. FEBS Lett. 315,
114–118.
34. Parra, L.A., Baust, T., El Mestikawy, S., Quiroz, M., Hoffman,
B., Haflett, J.M., Yao, J.K., and Torres, G.E. (2008). The orphan
transporter Rxt1/NTT4 (SLC6A17) functions as a synaptic
vesicle amino acid transporter selective for proline, glycine,
leucine, and alanine. Mol. Pharmacol. 74, 1521–1532.
35. Zaia, K.A., and Reimer, R.J. (2009). Synaptic vesicle protein
NTT4/XT1 (SLC6A17) catalyzes Naþ-coupled neutral amino
acid transport. J. Biol. Chem. 284, 8439–8448.
36. Felix, D., and Ku¨nzle, H. (1976). The role of proline in nervous
transmission. Adv. Biochem. Psychopharmacol. 15, 165–173.
37. Yoneda, Y., and Roberts, E. (1982). A new synaptosomal
biosynthetic pathway of proline from ornithine and its nega-
tive feedback inhibition by proline. Brain Res. 239, 479–488.396 The American Journal of Human Genetics 96, 386–396, March 538. Takemoto, Y., and Semba, R. (2006). Immunohistochemical
evidence for the localization of neurons containing the puta-
tive transmitter L-proline in rat brain. Brain Res. 1073-1074,
311–315.
39. Harsing, L.G., Jr., and Matyus, P. (2013). Mechanisms of
glycine release, which build up synaptic and extrasynaptic
glycine levels: the role of synaptic and non-synaptic glycine
transporters. Brain Res. Bull. 93, 110–119.
40. Newcomer, J.W., Farber, N.B., Jevtovic-Todorovic, V., Selke, G.,
Melson, A.K., Hershey, T., Craft, S., and Olney, J.W. (1999). Ke-
tamine-induced NMDA receptor hypofunction as a model of
memory impairment and psychosis. Neuropsychopharmacol-
ogy 20, 106–118.
41. Salomons, G.S., van Dooren, S.J., Verhoeven, N.M., Cecil,
K.M., Ball, W.S., Degrauw, T.J., and Jakobs, C. (2001).
X-linked creatine-transporter gene (SLC6A8) defect: a new
creatine-deficiency syndrome. Am. J. Hum. Genet. 68,
1497–1500.
42. Louis, E.D. (1999). A new twist for stopping the shakes? Revis-
iting GABAergic therapy for essential tremor. Arch. Neurol. 56,
807–808.
43. Ma´lly, J., Baranyi, M., and Vizi, E.S. (1996). Change in the con-
centrations of amino acids in CSF and serum of patients with
essential tremor. J. Neural Transm. 103, 555–560.
44. Kralic, J.E., Criswell, H.E., Osterman, J.L., O’Buckley, T.K.,
Wilkie, M.E., Matthews, D.B., Hamre, K., Breese, G.R., Ho-
manics, G.E., and Morrow, A.L. (2005). Genetic essential
tremor in gamma-aminobutyric acidA receptor alpha1 sub-
unit knockout mice. J. Clin. Invest. 115, 774–779.
45. D’Hulst, C., Heulens, I., Brouwer, J.R., Willemsen, R., De
Geest, N., Reeve, S.P., De Deyn, P.P., Hassan, B.A., and Kooy,
R.F. (2009). Expression of the GABAergic system in animal
models for fragile X syndrome and fragile X associated
tremor/ataxia syndrome (FXTAS). Brain Res. 1253, 176–183., 2015
